

DAFTAR PUSTAKA

- Abbas, Abul K., Lichtman, Andrew H., and Pillai, Shiv. (2016). *Imunologi Dasar Abbas: Fungsi dan Kelainan Sistem Imun*. Edisi Kelima. Elsevier.
- Abbasvandi, F., Bayat, M., Akbari, A., Shojaeian, F., Zandi, A., *et al.* (2023). Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. *Scientific reports*, 13(1), 16719. doi.org/10.1038/s41598-023-43186-8
- Al Murri, A.M., Hilmy, M., Bell, J., Wilson, C., McNicol, A.M., *et al.* (2008). The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. *British Journal of Cancer*, 99(7), pp. 1013–1019. doi.org/10.1038/sj.bjc.6604667
- An, Doyeon., Choi, J., Lee, J., Kim, J.Y., Kwon, S. *et al.* (2022). Time to surgery and survival in breast cancer. *BMC Surg* 22, p. 388. doi.org/10.1186/s12893-022-01835-1
- Bates, Joshua P., Derakhshandeh, Roshanak., Jones, Laundette., Webb. (2018). Mechanisms of immune evasion in breast cancer. *BMC Cancer*, 18, p. 556. doi.org/10.1186/s12885-018-4441-3
- Bayoumi, Y., Heikal, T., and Darweish, H. (2014). Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients. *Cancer management and research*, 6, pp. 459–465. doi.org/10.2147/CMAR.S69055
- Boyce-Fappiano, D., Bedrosian, I., Shen, Y. and *et al.* (2021). Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: A National Cancer Database analysis. *npj Breast Cancer*, 7, p. 87. doi.org/10.1038/s41523-021-00294-w

- Bronsveld, H.K., Jensen, V., Vahl, P., de Bruin, M.L., Cornelissen, S. *et al.* (2017), Diabetes and breast cancer subtypes. *PLoS ONE*, 12(1), p. e0170084. doi.org/10.1371/journal.pone.0170084
- Buonacera, A., Stancanelli, B., Colaci, M. and Malatino, L. (2022). Neutrophil to lymphocyte ratio: An emerging marker of the relationships between the immune system and diseases. *International Journal of Molecular Sciences*, 23(7), p. 3636. doi.org/10.3390/ijms23073636
- Chen, B., Dai, D., Tang, H., Ai, X., Chen, X. *et al.* (2016). Pretreatment hematocrit is superior to hemoglobin as a prognostic factor for triple negative breast cancer. *PLoS ONE*, 11(11), p. e0165133.
- Chen, F., Chen, D., Jin, L., Xu, C., Zhao, W., Hu, W. (2022) Prognostic Significance of Neutrophil-toLymphocyte Ratio and C-Reactive Protein/Albumin Ratio in Luminal Breast Cancers With HER2-Negativity. *Frontiers in Oncology* 12:845935. doi: 10.3389/fonc.2022.845935
- Chen, L., Bai, P., Kong, X., Huang, S., Wang, Z., *et al.* (2021). Prognostic nutritional index (PNI) in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. *Frontiers in Cell and Developmental Biology*, 9, p. 656741. doi.org/10.3389/fcell.2021.656741
- Cheung, Kwok-Leung. (2020). Treatment Strategies and Survival Outcomes in Breast Cancer. *Cancers*, 12, 735; doi:10.3390/cancers12030735
- Chow, Melvyn., Moller, A., Smytha, M. (2012). Inflammation and immune surveillance in cancer. *Seminars in Cancer Biology*, 22, pp. 23–32. doi:10.1016/j.semcancer.2011.12.004
- Cilibrasi, C., Papanastasopoulos, P., Samuels, M., Giamas, G. (2021). Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. *Int. J. Mol. Sci.*, 22. doi.org/10.3390/ijms222112015

- Davey, M.G., Hynes, S.O., Kerin, M.J., Miller, N., Lowery, A.J. (2021). Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. *Cancers (Basel)*.13(17) p. 4455. doi: 10.3390/cancers13174455. PMID: 34503265; PMCID: PMC8430879.
- Dou, X., Wang, R.B., Yan, H.J., Jiang, S.M., Meng, X.J. and et al. (2013). Circulating lymphocytes as predictors of sensitivity to preoperative chemoradiotherapy in rectal cancer cases. *Asian Pacific Journal of Cancer Prevention*, 14(6), pp. 3881-3885. doi.org/10.7314/apjcp.2013.14.6.3881. PMID: 23886201
- Eriksson, L., Bergh, J., Humphreys, K., Warnberg, F., Tornberg, S. Czene, K. (2018) Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study. *Int. J. Cancer*: 143, 1093–1104 (2018) DOI: 10.1002/ijc.31411
- Farhood, B., Najafi, M. and Mortezaee, K. (2019). CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. *Journal of Cellular Physiology*, 234(6), pp. 8509–8521. doi.org/10.1002/jcp.27782
- Fayaz, S., Demian, G.A., El-Sherify, M., Eissa, H., Aziz, M. et al. (2019). Triple negative breast cancer: 10-year survival update of the applied treatment strategy in Kuwait. *The Gulf Journal of Oncology*, 1(29), pp. 53-59.
- Fuca, Giovanni., Guarini, V., Antoniotti, C., Morano, F., Moretto, R., Corallo, S., Mormorino, F., Lonardi, S., Rimassa, L., et al. (2021). The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. *British Journal of Cancer* (2020) 123:403–409; doi.org/10.1038/s41416-020-0894-7
- Gao, Q.L., Shi, J.G. and Huang, Y.D. (2021). Prognostic significance of pretreatment prognostic nutritional index (PNI) in patients with nasopharyngeal carcinoma: A meta-analysis. *Nutrition and Cancer*, 73(9), pp. 1657–1667. doi.org/10.1080/01635581.2020.1810715

- Gong, Z., Li, Q., Shi, J., Li, P., Hua, L. *et al.* (2022). Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis. *Science Immunology*, 8, p. eadd5204. doi.org/10.1126/sciimmunol.add5204
- Gonzalez, H., Hagerling, C. and Werb, Z. (2018). Roles of the immune system in cancer: From tumor initiation to metastatic progression. *Genes & Development*, 32, pp. 1267–1284. doi.org/10.1101/gad.314617.118
- Hanahan, Douglas., Monje, Michelle. (2023) Cancer hallmarks intersect with neuroscience in the tumor microenvironment. *Cancer Cell*, Volume 41, Issue 3, 2023, Pages 573-580, ISSN 1535-6108, doi.org/10.1016/j.ccell.2023.02.012.
- Hill, Deirdre., Argyropoulos, C., Roumelioti, M., Unruh, M. (2020) Chronic kidney disease in breast cancer treatment and survival. *Cancer Res* (2020) 80 (4_Supplement): P5-07-14. doi.org/10.1158/1538-7445.SABCS19-P5-07-14
- Hong, R. and Xu, B. (2022). Breast cancer: An up-to-date review and future perspectives. *Cancer Communications*, 42, pp. 913–936. doi.org/10.1002/cac2.12358
- Hua, X., Long, Z. Q., Huang, X., Deng, J. P., He, Z. Y. *et al.* (2020). The Value of Prognostic Nutritional Index (PNI) in Predicting Survival and Guiding Radiotherapy of Patients With T1-2N1 Breast Cancer. *Frontiers in Oncology*, 9, 1562. doi.org/10.3389/fonc.2019.01562.
- Ishizuka, Y., Horimoto, Y., Morita, M., Kawamura, Y., Sekine, K., *et al.* (2023). The impact of being underweight on the prognosis of older patients with early breast cancer. *Cancer Diagnosis & Prognosis*, 3(6), pp. 678–686. doi.org/10.21873/cdp.10272
- Jiang, C., Xiu, Y., Yu, X., Qiao, K., Zhang, S. *et al.* (2022). Prognostic value of a modified systemic inflammation score in breast cancer patients who

underwent neoadjuvant chemotherapy. *BMC Cancer*, 22, p. 1249.
doi.org/10.1186/s12885-022-10291-2

Kaiser, R., Escaig, R., Erber, J. and Nicolai, L. (2022). Neutrophil-platelet interactions as novel treatment targets in cardiovascular disease. *Frontiers in Cardiovascular Medicine*, 8, p. 824112. doi.org/10.3389/fcvm.2021.824112

Kasper, D.L., Longo, D.L. and Fauci, A.S. (2016). Breast cancer, in *Harrison's Principles of Internal Medicine*. 19th edn. London: McGraw-Hill, pp. 316–321.

Koelwyn, G.J., Newman, A.A.C., Afonso, M.S., van Solingen, C., Corr, E.M., *et al.* (2020). Myocardial infarction accelerates breast cancer via innate immune reprogramming. *Nature Medicine*, 26(9), pp. 1452–1458.
doi.org/10.1038/s41591-020-0964-7

Kubota, K., Ito, R., Narita, N., Tanaka, Y., Furudate, K. *et al.* (2022). Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment. *BMC Cancer*, 22(1), p. 368. doi.org/10.1186/s12885-022-09439-x

Lee, E.T. and Wang, J.W. (2003). *Statistical methods for survival data analysis*, 3rd edn, Wiley, New York. doi.org/10.1002/0471458546

Lee, Y., Kang, E., Shin, H.C., Lee, H., Yoon, K. *et al.* (2021). The effect of body mass index on initial breast cancer stage among Korean women. *Clinical Breast Cancer*, 21(6), pp. e631-e637. doi: 10.1016/j.clbc.2021.04.007.

Li, M., Quintana, A., Alberts, E., Hung, M.S., Boulat, V. *et al.* (2023). B cells in breast cancer pathology. *Cancers (Basel)*, 15(5), p. 1517.
doi.org/10.3390/cancers15051517

Li, Z., Shen, G., Shen, S., Shi, M., Zheng, Y. *et al.* (2023). Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis. *Cancer Pathogenesis and Therapy*.
doi.org/10.1016/j.cpt.2023.03.002

- Ligorio, F., Fucà, G., Zattarin, E., Lobefaro, R., Zambelli, L. *et al.* (2021). The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab pertuzumab. *Cancers*, 13, p. 1964. doi.org/10.3390/cancers13081964
- Lipscombe, L.L., Fischer, H.D., Austin, P.C., Fu, J., Jaakkimainen, R.L. *et al.* (2015). The association between diabetes and breast cancer stage at diagnosis: a population-based study. *Breast Cancer Research and Treatment*, 150, pp. 613–620. doi.org/10.1007/s10549-015-3323-5
- Liu, X., Guo, X. and Zhang, Z. (2021). Preoperative serum hypersensitive C-reactive protein (hs-CRP) to albumin ratio predicts survival in patients with luminal B subtype breast cancer. *OncoTargets and Therapy*, 14, pp. 4137–4148.
- Luan, C. W., Tsai, Y. T., Yang, H. Y., Chen, K. Y., Chen, P. H. *et al.* (2021). Pretreatment prognostic nutritional index as a prognostic marker in head and neck cancer: a systematic review and meta-analysis. *Scientific reports*, 11(1), 17117. <https://doi.org/10.1038/s41598-021-96598-9>
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R. *et al.* (2021). Breast cancer epidemiology, risk factors, classification, prognostic markers, and current treatment strategies: An updated review. *Cancers*, 13, p. 4287. doi.org/10.3390/cancers13174287
- Matsui, R., Rifu, K., Watanabe, J., Inaki, N. and Fukunaga, T. (2023). Impact of malnutrition as defined by the GLIM criteria on treatment outcomes in patients with cancer: A systematic review and meta-analysis. *Clinical Nutrition*, 42(5), pp. 615-624. doi.org/10.1016/j.clnu.2023.02.019
- Mehta, L.S., Watson, K.E., Barac, A., Beckie, T.M., Bittner, V. *et al.* (2018). Cardiovascular disease and breast cancer: Where these entities intersect: A scientific statement from the American Heart Association. *Circulation*, 137(8), pp. e30–e66. doi.org/10.1161/CIR.0000000000000556

- Mangaonkar, A., Tande, A.J. and Bekele, D.I. (2021). Differential diagnosis and workup of monocytosis: A systematic approach to a common hematologic finding. *Current Hematologic Malignancy Reports*, 16(3), pp. 267–275. doi.org/10.1007/s11899-021-00618-4
- Mohri, T., Mohri, Y., Shigemori, T., Takeuchi, K., Itoh, Y., & Kato, T. (2016). Impact of prognostic nutritional index on long-term outcomes in patients with breast cancer. *World journal of surgical oncology*, 14(1), 170. <https://doi.org/10.1186/s12957-016-0920-7>
- Moon, H.G., Han, W. and Noh, D.Y. (2009). Underweight and breast cancer recurrence and death: A report from the Korean Breast Cancer Society. *Journal of Clinical Oncology*, 27(35), pp. 5899–5905. doi.org/10.1200/JCO.2009.22.4436
- Muhartono, H., Hanriko, R. and Suharyani (2020). Correlation of lymphocyte-monocyte ratio with grading of breast cancer malignancy. *Bioscientia Medicina*, 4(3), pp. 10–18.
- Oba, T., Maeno, K., Takekoshi, D., Ono, M., Ito, T. *et al.* (2020). Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer. *BMC Cancer*, 20(1), 160. doi.org/10.1186/s12885-020-6647-4.
- Pascual, M.C., Montaña, J.J., Franch, P., Sánchez-Contador, C. and Ramos, M. (2022). Survival of breast cancer by stage, grade and molecular groups in Mallorca, Spain. *Journal of Clinical Medicine*, 11(19), p. 5708. doi.org/10.3390/jcm11195708
- Peng, P., Chen, L., Shen, Q., Xu, Z. and Ding, X. (2023). Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score for predicting outcomes of breast cancer: A systematic review and meta-analysis. *Pakistani Journal of Medical Sciences*, 39(5), pp. 1535–1541. doi.org/10.12669/pjms.39.5.7781

Provenzano, L., Lobefaro, R., Ligorio, F., Zattarin, E., Zambelli, L. *et al.* (2023).

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: An institutional retrospective analysis. *Therapeutic Advances in Medical Oncology*, 15, pp. 1–15. doi.org/10.1177/17588359231165978

Qi, X., Qiao, B., Song, T., Huang, D., Zhang, H., Liu, Y., Jin, Q., Yang, M., & Liu, D. (2023). Clinical utility of the pan-immune-inflammation value in breast cancer patients. *Frontiers in oncology*, 13, 1223786. <https://doi.org/10.3389/fonc.2023.1223786>

Ravasco, P. (2019). Nutrition in cancer patients. *Journal of Clinical Medicine*, 8(8), p. 1211. doi.org/10.3390/jcm8081211. PMID: 31416154; PMCID: PMC6723589

Rizzo, A. and Ricci, A.D. (2022). Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. *Expert Opinion on Investigational Drugs*, 31(6), pp. 549–555. doi.org/10.1080/13543784.2022.2008354

Rossi, L., Stevens, D., Pierga, J-Y., Lerebours, F., Reyal, F. *et al.* (2015). Impact of adjuvant chemotherapy on breast cancer survival: A real-world population. *PLOS ONE*, 10(7), p. e0132853. doi.org/10.1371/journal.pone.0132853

Rutqvist, L.E., Rose, C. and Cavallin-Ståhl, E. (2003). A systematic overview of radiation therapy effects in breast cancer. *Acta Oncologica (Stockholm, Sweden)*, 42(5-6), pp. 532–545. doi.org/10.1080/02841860310014444

Schoenfeld, D.A. (1983). Sample-size formula for the proportional-hazards regression model. *Biometrics*, 39, pp. 499-503. <http://dx.doi.org/10.2307/2531021>

Shah, R., Rosso, K. and Nathanson, S.D. (2014). Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World Journal of Clinical Oncology*, 5(3), pp. 283–298. doi.org/10.5306/wjco.v5.i3.283

- Silva, A.S., França, A.C.W., Padilla, M.P., Macedo, L.S., Magliano, C.A.d.S. *et al.* (2022). Brazilian breast cancer patient-reported outcomes: What really matters for these women. *Frontiers in Medical Technology*, 4, p. 809222. doi.org/10.3389/fmedt.2022.809222
- Sinaga, E.S., Ahmad, R.A., Shivalli, S. and Hutajulu, S.H. (2018). Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. *Pan African Medical Journal*, 31, p. 163. doi.org/10.11604/pamj.2018.31.163.17284
- Smolarz, B., Nowak, A.Z. and Romanowicz, H. (2022). Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *Cancers*, 14(10), p. 2569. doi.org/10.3390/cancers14102569
- Soeters, P.B., Wolfe, R.R. and Shenkin, A. (2019). Hypoalbuminemia: Pathogenesis and clinical significance. *Journal of Parenteral and Enteral Nutrition*, 43, pp. 181–193. doi.org/10.1002/jpen.1451
- Su, Y., Yao, Q., Xu, Y., Yu, C., Zhang, J. *et al.* (2021). Characteristics of germline non-BRCA mutation status of high-risk breast cancer patients in China and correlation with high-risk factors and multigene testing suggestions', *Frontiers in Genetics*, 12, p. 674094. doi.org/10.3389/fgene.2021.674094
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I. *et al.* (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71, pp. 209–249. doi: 10.3322/caac.21660.
- Swann, J.B. and Smyth, M.J. (2007). Immune surveillance of tumors. *Journal of Clinical Investigation*, 117(5), pp. 1137-1146. doi.org/10.1172/JCI31405
- Waks, A.G. and Winer, E.P. (2019). Breast Cancer Treatment: A Review. *JAMA*, 321(3), pp. 288-300. doi.org/10.1001/jama.2018.19323

- Wang, H., Li, L. and Ma, Y. (2023). Platelet-to-lymphocyte ratio: A potential prognosticator in acute myocardial infarction: A prospective longitudinal study. *Clinical Cardiology*, pp. 1-7. doi.org/10.1002/clc.24002
- Wang, R., Zhu, Y., Liu, X., Liao, X., He, J. *et al.* (2019). The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. *BMC Cancer*, 19(1), p. 1091. doi.org/10.1186/s12885-019-6311-z
- Wang, X., Wang, N., Zhong, L., Wang, S., Zheng, Y. *et al.* (2020). Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. *Molecular Psychiatry*, 25(12), pp. 3186–3197. doi.org/10.1038/s41380-020-00865-6
- Wang, Z., Wang, Y., Zhang, X., and Zhang, T. (2018). Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysis. *Clinica Chimica Acta: International Journal of Clinical Chemistry*, 486, pp. 303–310. doi.org/10.1016/j.cca.2018.08.030
- Wiener, A.A., Hanlon, B.M., Schumacher, J.R., Vande Walle, K.A., Wilke, L.G. *et al.* (2023). Reexamining time from breast cancer diagnosis to primary breast surgery. *JAMA Surgery*, 158(5), pp. 485–492. doi.org/10.1001/jamasurg.2022.8388
- Wiranata, S., Anjani, I.A.W., Saputra, I.P.G., Sadvika, I.G.A.S., Prabawa, I.P.Y. *et al.* (2020). Pretreatment Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as a Stage Determination in Breast Cancer. *Macedonian Journal of Medical Sciences*, 8(B), pp. 1058-1063. doi.org/10.3889/oamjms.2020.5336
- Woo, J., Moon, B. I., Kwon, H., & Lim, W. (2022). Effect of radiotherapy sequence on long-term outcome in patients with node-positive breast cancer: a retrospective study. *Scientific Reports*, 12(1), p. 10729. doi: 10.1038/s41598-022-14873-9.

- Xiang, Y., Zhang, N., Lei, H., Wu, J., Wang, W. *et al.* (2022). Neutrophil-lymphocyte ratio is a negative prognostic biomarker for luminal A breast cancer. *Research Square*. doi: 10.21203/rs.3.rs-1835908/v1.
- Xiong, J. & Wang, Q. (2021). Suppressive myeloid cells shape the tumor immune microenvironment. *Advanced Biosystems*, February. doi: 10.1002/adbi.201900311.
- Xu, T., Zhang, S. M., Wu, H. M., Wen, X. M., Qiu, D. Q. *et al.* (2022). Prognostic significance of prognostic nutritional index and systemic immune-inflammation index in patients after curative breast cancer resection: a retrospective cohort study. *BMC Cancer*, 22(1), 1128. doi.org/10.1186/s12885-022-10218-x.
- Yu, P. & Fu, Y.X. (2006). Tumor-infiltrating T lymphocytes: friends or foes?. *Lab Investigation*, 86(3), pp. 231-245. doi: 10.1038/labinvest.3700389.
- Zhang, K., Ping, L., Ou, X., Bazhabayi, M. and Xiao, X. (2021). A systemic inflammation response score for prognostic prediction of breast cancer patients undergoing surgery. *Journal of Personalized Medicine*, 11(5), p. 413. doi: 10.3390/jpm11050413.
- Zhang, W., Shen, Y., Huang, H., Pan, S., Jiang, J. *et al.* (2020). A Rosetta Stone for breast cancer: Prognostic value and dynamic regulation of neutrophil in tumor microenvironment. *Frontiers in Immunology*, 11, p. 1779. doi: 10.3389/fimmu.2020.01779.
- Zhang, Xu., Zhang, Wen., Yuan, X., Fu, M., Qian, H. (2016). Neutrophils in cancer development and progression: Roles, mechanisms, and implications (Review). *International Journal of Oncology* 49, no. 3 (2016): 857-867. doi.org/10.3892/ijo.2016.3616
- Zhang, X.W., Ge, Y.Z., Song, M.M., Ruan, G.T., Xie, H.L. *et al.* (2023). Prognostic power of nutrition-inflammation indicators in patients with breast cancer.

Clinical Breast Cancer, 23(5), pp. e312–e321.
doi.org/10.1016/j.clbc.2023.04.009

Zhu, M., Chen, L., Kong, X., Wang, X., Fang, Y. *et al.* (2022). The systemic inflammation response index as an independent predictor of survival in breast cancer patients: A retrospective study. *Frontiers in Molecular Biosciences*, 9, p. 856064. doi: 10.3389/fmolb.2022.856064.

Zhu, Y., Si, W., Sun, Q., Qin, B., Zhao, W. *et al.* (2017). Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer. *Oncotarget*, 8(1), pp. 1023-1030. doi: 10.18632/oncotarget.13714.